'For the quarter ending March 2024, consolidated net sales (including other operating income) of Gland Pharma has increased 95.85% to Rs 1537.45 crore compared to quarter ended March 2023.  Operating profit margin has jumped from 21.45% to 23.33%, leading to 112.96% rise in operating profit to Rs 358.65 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 50.87% to 37.82%.   Purchase of finished goods cost rose from 0.37% to 0.44%.   Employee cost increased from 11.93% to 23.14%.   Other expenses fell from 17.28% to 14.99%.   Power and Oil fuel cost rose from 3.42% to 3.81%.   

Other income rose 8.24% to Rs 42.15 crore.  PBIDT rose 93.30% to Rs 400.8 crore.  Provision for interest rose 352.73% to Rs 9.96 crore.  Loan funds rose to Rs 372.17 crore as of 31 March 2024 from Rs 4.45 crore as of 31 March 2023.  Inventories declined from...

• 

  (01-Mar-2025)

  Foseco India

  OP up 17%
• 

  (28-Feb-2025)

  Schaeffler India

  Maintains double digit revenue growth and stable OPM
• 

  (28-Feb-2025)

  Sanofi India

  OP up 18.78%
• 

  (28-Feb-2025)

  KSB

  Net up 33% largely on higher sales, higher OI and lower taxation